Interacciones de Ramipril

Ramipril (Altace), inhibidor de la ECA, tiene 203 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 33; moderadas: 142; leves: 28; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 0. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.

Interacciones según la etiqueta

Interacciones graves (33)

  • AliskirenoantihipertensivoGrave

    Do not co-administer ramipril capsules with aliskiren: in patients with diabetes Angioedema related to previous treatment with an ACE inhibitor, or a history of hereditary or idiopathic angioedema (4). (etiqueta de Ramipril, Contraindicaciones)

  • Amlodipino y benazeprilbloqueador de los canales de calcio dihidropiridínicoGrave

    Ramipril capsules is contraindicated in patients who are hypersensitive to this product or any other ACE inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). (etiqueta de Ramipril, Contraindicaciones)

  • Amlodipino y valsartánbloqueador de los canales de calcio dihidropiridínicoGrave

    Do not administer ramipril within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor [see Warnings and Precautions (5.1) ] . (etiqueta de Ramipril, Contraindicaciones)

  • Benazeprilinhibidor de la ECAGrave

    Ramipril capsules is contraindicated in patients who are hypersensitive to this product or any other ACE inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). (etiqueta de Ramipril, Contraindicaciones)

  • Benazepril e hidroclorotiazidainhibidor de la ECAGrave

    Ramipril capsules is contraindicated in patients who are hypersensitive to this product or any other ACE inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). (etiqueta de Ramipril, Contraindicaciones)

  • Candesartánantagonista de los receptores de la angiotensina II (ARA-II)Grave

    Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (etiqueta de Candesartán, Interacciones medicamentosas)

  • Captoprilinhibidor de la ECAGrave

    Ramipril capsules is contraindicated in patients who are hypersensitive to this product or any other ACE inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). (etiqueta de Ramipril, Contraindicaciones)

  • ClozapinaantipsicóticoGrave

    Use CLOZARIL cautiously in patients with cardiovascular or cerebrovascular disease or conditions predisposing to hypotension (e.g., dehydration, use of antihypertensive medications) [see Dosage and Administration ( 2.2 , 2.6 ), Warnings and Precautions ( 5.2 )]. (etiqueta de Clozapina, Advertencia en recuadro)

  • Enalaprilinhibidor de la ECAGrave

    Ramipril capsules is contraindicated in patients who are hypersensitive to this product or any other ACE inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). (etiqueta de Ramipril, Contraindicaciones)

  • Enalapril e hidroclorotiazidainhibidor de la ECAGrave

    Ramipril capsules is contraindicated in patients who are hypersensitive to this product or any other ACE inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). (etiqueta de Ramipril, Contraindicaciones)

  • Enalaprilatoinhibidor de la ECAGrave

    Ramipril capsules is contraindicated in patients who are hypersensitive to this product or any other ACE inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). (etiqueta de Ramipril, Contraindicaciones)

  • Eptifibatidaantiagregante plaquetarioGrave

    …of active abnormal bleeding within the previous 30 days Severe hypertension (systolic blood pressure >200 mm Hg or diastolic blood pressure >110 mm Hg) not adequately controlled on antihypertensive therapy Major surgery within the preceding 6 weeks History of stroke within 30 days or any history of hemorrhagic stroke Current or planned administration of another… (etiqueta de Eptifibatida, Contraindicaciones)

  • EverolimusinmunosupresorGrave

    Avoid the concomitant use of ACE inhibitors with AFINITOR/AFINITOR DISPERZ [see Warnings and Precautions (5.4)] . (etiqueta de Everolimus, Interacciones medicamentosas)

  • Fosinoprilinhibidor de la ECAGrave

    Ramipril capsules is contraindicated in patients who are hypersensitive to this product or any other ACE inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). (etiqueta de Ramipril, Contraindicaciones)

  • Fosinopril e hidroclorotiazidainhibidor de la ECAGrave

    Ramipril capsules is contraindicated in patients who are hypersensitive to this product or any other ACE inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). (etiqueta de Ramipril, Contraindicaciones)

  • Irbesartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Grave

    In patients whose renal function may depend on the activity of the renin-angiotensin-aldosterone system (e.g., patients with severe congestive heart failure), treatment with ACE inhibitors has been associated with oliguria and/or progressive azotemia and (rarely) with acute renal failure and/or death. (etiqueta de Irbesartán e hidroclorotiazida, Advertencias y precauciones)

  • Lisinoprilinhibidor de la ECAGrave

    Ramipril capsules is contraindicated in patients who are hypersensitive to this product or any other ACE inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). (etiqueta de Ramipril, Contraindicaciones)

  • Lisinopril e hidroclorotiazidainhibidor de la ECAGrave

    Ramipril capsules is contraindicated in patients who are hypersensitive to this product or any other ACE inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). (etiqueta de Ramipril, Contraindicaciones)

  • Metolazonadiurético tiazídicoGrave

    Other Antihypertensive Drugs When metolazone tablets, USP, are used with other antihypertensive drugs, particular care must be taken to avoid excessive reduction of blood pressure, especially during initial therapy. (etiqueta de Metolazona, Advertencias)

  • MinoxidilvasodilatadorGrave

    Minoxidil should be reserved for hypertensive patients who do not respond adequately to maximum therapeutic doses of a diuretic and two other antihypertensive agents. (etiqueta de Minoxidil, Advertencia en recuadro)

  • Moexiprilinhibidor de la ECAGrave

    Ramipril capsules is contraindicated in patients who are hypersensitive to this product or any other ACE inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). (etiqueta de Ramipril, Contraindicaciones)

  • Perindoprilinhibidor de la ECAGrave

    Ramipril capsules is contraindicated in patients who are hypersensitive to this product or any other ACE inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). (etiqueta de Ramipril, Contraindicaciones)

  • PotasioVitaminas y mineralesGrave

    Estos medicamentos reducen la excreción de potasio; añadir suplementos de potasio o sustitutos de la sal puede causar hiperpotasemia, que afecta al ritmo cardíaco. (NIH Office of Dietary Supplements, Potassium)

  • Quinaprilinhibidor de la ECAGrave

    Ramipril capsules is contraindicated in patients who are hypersensitive to this product or any other ACE inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). (etiqueta de Ramipril, Contraindicaciones)

  • Quinapril e hidroclorotiazidainhibidor de la ECAGrave

    Ramipril capsules is contraindicated in patients who are hypersensitive to this product or any other ACE inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). (etiqueta de Ramipril, Contraindicaciones)

  • Sacubitrilo y valsartánantagonista de los receptores de la angiotensina II (ARA-II)Grave

    Ramipril capsules are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). (etiqueta de Ramipril, Contraindicaciones)

  • Tadalafiloinhibidor de la PDE5Grave

    …coadministration of an alpha-blocker and CIALIS for the treatment of BPH has not been adequately studied, and due to the potential vasodilatory effects of combined use resulting in blood pressure lowering, the combination of CIALIS and alpha-blockers is not recommended for the treatment of BPH. [see Dosage and Administration ( 2.7 ), Drug Interactions ( 7.1 ),… (etiqueta de Tadalafilo, Advertencias y precauciones)

  • Telmisartánantagonista de los receptores de la angiotensina II (ARA-II)Grave

    Patients receiving the combination of telmisartan and ramipril did not obtain any benefit in the composite endpoint of cardiovascular death, MI, stroke and heart failure hospitalization compared to monotherapy, but experienced an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, or dialysis) compared with groups… (etiqueta de Ramipril, Advertencias y precauciones)

  • Telmisartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Grave

    Patients receiving the combination of telmisartan and ramipril did not obtain any benefit in the composite endpoint of cardiovascular death, MI, stroke and heart failure hospitalization compared to monotherapy, but experienced an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, or dialysis) compared with groups… (etiqueta de Ramipril, Advertencias y precauciones)

  • Telmisartán y amlodipinoantagonista de los receptores de la angiotensina II (ARA-II)Grave

    Patients receiving the combination of telmisartan and ramipril did not obtain any benefit in the composite endpoint of cardiovascular death, MI, stroke and heart failure hospitalization compared to monotherapy, but experienced an increased incidence of clinically important renal dysfunction (death, doubling of serum creatinine, or dialysis) compared with groups… (etiqueta de Ramipril, Advertencias y precauciones)

  • Trandolaprilinhibidor de la ECAGrave

    Ramipril capsules is contraindicated in patients who are hypersensitive to this product or any other ACE inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ACE inhibitor). (etiqueta de Ramipril, Contraindicaciones)

  • Valsartánantagonista de los receptores de la angiotensina II (ARA-II)Grave

    Do not administer ramipril within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor [see Warnings and Precautions (5.1) ] . (etiqueta de Ramipril, Contraindicaciones)

  • Valsartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Grave

    Do not administer ramipril within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor [see Warnings and Precautions (5.1) ] . (etiqueta de Ramipril, Contraindicaciones)

Interacciones moderadas (142)

  • Acetazolamidainhibidor de la anhidrasa carbónicaModerada

    Experience with another ACE inhibitor suggests that these increases would be reversible upon discontinuation of ramipril and/or diuretic therapy. (etiqueta de Ramipril, Advertencias y precauciones)

  • NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect (7.6). mTOR inhibitor or neprilysin inhibitor use may increase angioedema risk (7.7). (etiqueta de Ramipril, Interacciones medicamentosas)

  • Ácido acetilsalicílico y dipiridamolantiagregante plaquetarioModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect (7.6). mTOR inhibitor or neprilysin inhibitor use may increase angioedema risk (7.7). (etiqueta de Ramipril, Interacciones medicamentosas)

  • Ácido etacrínicodiurético de asaModerada

    Experience with another ACE inhibitor suggests that these increases would be reversible upon discontinuation of ramipril and/or diuretic therapy. (etiqueta de Ramipril, Advertencias y precauciones)

  • Ácido mefenámicoAINEModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect (7.6). mTOR inhibitor or neprilysin inhibitor use may increase angioedema risk (7.7). (etiqueta de Ramipril, Interacciones medicamentosas)

  • AdrenalinasimpaticomiméticoModerada

    Epinephrine may antagonize the neuronal blockade produced by guanethidine resulting in decreased antihypertensive effect and requiring increased dosage of the latter. (etiqueta de Adrenalina, Interacciones medicamentosas)

  • AlfuzosinaalfabloqueanteModerada

    Postural hypotension/syncope: Care should be taken in patients with symptomatic hypotension or who have had a hypotensive response to other medications or are concomitantly treated with antihypertensive medication or nitrates ( 5.1 ) (etiqueta de Alfuzosina, Advertencias y precauciones)

  • AlteplasaModerada

    In the post-marketing setting, there have been reports of angioedema in patients (primarily patients with AIS) receiving concomitant angiotensin-converting enzyme inhibitors. [see Warnings and Precautions (5.2) ]. (etiqueta de Alteplasa, Interacciones medicamentosas)

  • Amiloridadiurético ahorrador de potasioModerada

    Experience with another ACE inhibitor suggests that these increases would be reversible upon discontinuation of ramipril and/or diuretic therapy. (etiqueta de Ramipril, Advertencias y precauciones)

  • Amlodipino y olmesartánbloqueador de los canales de calcio dihidropiridínicoModerada

    Dual Blockade of the Renin-Angiotensin System Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. (etiqueta de Ramipril, Advertencias y precauciones)

  • Anfepramonaestimulante del SNCModerada

    The pressor effects of diethylpropion and those of other drugs may be additive when the drugs are used concomitantly; conversely, diethylpropion may interfere with antihypertensive drugs (i.e., guanethidine, a-methyldopa). (etiqueta de Anfepramona, Interacciones medicamentosas)

  • AripiprazolantipsicóticoModerada

    Antihypertensive Drugs Due to its alpha-adrenergic antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents. (etiqueta de Aripiprazol, Interacciones medicamentosas)

  • Armodafiniloestimulante del SNCModerada

    There was also a slightly greater proportion of patients on NUVIGIL requiring new or increased use of antihypertensive medications (2.9%) compared to patients on placebo (1.8%). (etiqueta de Armodafinilo, Advertencias y precauciones)

  • AsenapinaantipsicóticoModerada

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medications, patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), and patients… (etiqueta de Asenapina, Advertencias y precauciones)

  • AtenololbetabloqueanteModerada

    Because of its relative beta 1 selectivity, however, TENORMIN may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (etiqueta de Atenolol, Advertencias)

  • Atenolol y clortalidonabetabloqueanteModerada

    Experience with another ACE inhibitor suggests that these increases would be reversible upon discontinuation of ramipril and/or diuretic therapy. (etiqueta de Ramipril, Advertencias y precauciones)

  • Atomoxetinainhibidor de la recaptación de noradrenalinaModerada

    Antihypertensive Drugs Prevention or Management Increase the frequency of monitoring blood pressure and adjust atomoxetine oral solution dosage as clinically appropriate. (etiqueta de Atomoxetina, Interacciones medicamentosas)

  • Avanafiloinhibidor de la PDE5Moderada

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (etiqueta de Avanafilo, Advertencias y precauciones)

  • Azilsartánantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Dual Blockade of the Renin-Angiotensin System Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. (etiqueta de Ramipril, Advertencias y precauciones)

  • Benzfetaminaestimulante del SNCModerada

    Amphetamines may decrease the hypotensive effect of antihypertensives. (etiqueta de Benzfetamina, Interacciones medicamentosas)

  • BisoprololbetabloqueanteModerada

    Because of its relative beta 1 -selectivity, however, BISOPROLOL FUMARATE may be used with caution in patients with bronchospastic disease who do not respond to, or who cannot tolerate other antihypertensive treatment. (etiqueta de Bisoprolol, Advertencias)

  • Bisoprolol e hidroclorotiazidabetabloqueanteModerada

    Experience with another ACE inhibitor suggests that these increases would be reversible upon discontinuation of ramipril and/or diuretic therapy. (etiqueta de Ramipril, Advertencias y precauciones)

  • BortezomibModerada

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (etiqueta de Bortezomib, Advertencias y precauciones)

  • BrexpiprazolantipsicóticoModerada

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, concomitant treatment with antihypertensive medication), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (etiqueta de Brexpiprazol, Advertencias y precauciones)

  • Brimonidinaagonista alfa-adrenérgicoModerada

    Antihypertensives/Cardiac Glycosides Because brimonidine tartrate ophthalmic solution 0.1% and 0.15% may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate ophthalmic solution 0.1% and 0.15% is advised. (etiqueta de Brimonidina, Interacciones medicamentosas)

  • Brimonidina y timololagonista alfa-adrenérgicoModerada

    Antihypertensives/Cardiac Glycosides Because brimonidine tartrate/timolol maleate ophthalmic solution may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with brimonidine tartrate/timolol maleate ophthalmic solution is advised. (etiqueta de Brimonidina y timolol, Interacciones medicamentosas)

  • Central Nervous System (CNS) depressants Antihistamines have additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, antianxiety agents, etc.). Antihypertensive drugs Sympathomimetic may reduce the effects of antihypertensive drugs. (etiqueta de Bromfeniramina, pseudoefedrina y dextrometorfano, Interacciones medicamentosas)

  • Bromocriptinaagonista de la dopaminaModerada

    Use caution in patients taking antihypertensive medications. (etiqueta de Bromocriptina, Advertencias y precauciones)

  • Bumetanidadiurético de asaModerada

    Experience with another ACE inhibitor suggests that these increases would be reversible upon discontinuation of ramipril and/or diuretic therapy. (etiqueta de Ramipril, Advertencias y precauciones)

  • NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect (7.6). mTOR inhibitor or neprilysin inhibitor use may increase angioedema risk (7.7). (etiqueta de Ramipril, Interacciones medicamentosas)

  • NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect (7.6). mTOR inhibitor or neprilysin inhibitor use may increase angioedema risk (7.7). (etiqueta de Ramipril, Interacciones medicamentosas)

  • Candesartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Experience with another ACE inhibitor suggests that these increases would be reversible upon discontinuation of ramipril and/or diuretic therapy. (etiqueta de Ramipril, Advertencias y precauciones)

  • CarbidopaModerada

    Symptomatic postural hypotension has occurred when carbidopa, given with levodopa or carbidopa-levodopa combination products, was added to the treatment of a patient receiving antihypertensive drugs. (etiqueta de Carbidopa, Interacciones medicamentosas)

  • Carbidopa y levodopafármaco dopaminérgicoModerada

    Antihypertensive drugs: May cause symptomatic postural hypotension. (etiqueta de Carbidopa y levodopa, Interacciones medicamentosas)

  • Carbidopa, levodopa y entacaponafármaco dopaminérgicoModerada

    Antihypertensive Agents Symptomatic postural hypotension has occurred when carbidopa/levodopa was added to the treatment of patients receiving antihypertensive drugs. (etiqueta de Carbidopa, levodopa y entacapona, Interacciones medicamentosas)

  • CariprazinaantipsicóticoModerada

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (etiqueta de Cariprazina, Advertencias y precauciones)

  • CarvedilolbetabloqueanteModerada

    COREG may be used with caution, however, in patients who do not respond to, or cannot tolerate, other antihypertensive agents. (etiqueta de Carvedilol, Advertencias y precauciones)

  • CelecoxibAINEModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect (7.6). mTOR inhibitor or neprilysin inhibitor use may increase angioedema risk (7.7). (etiqueta de Ramipril, Interacciones medicamentosas)

  • Ciclobenzaprinarelajante muscularModerada

    …concomitant use of TONMYA with: MAO inhibitors may be life-threatening [see Contraindications (4) ] , Alcohol, barbiturates, and other CNS depressants may increase the risk of adverse reactions associated with these drugs, Tramadol may increase the seizure risk, Guanethidine or other similar acting drugs may block the antihypertensive action of these drugs. (etiqueta de Ciclobenzaprina, Interacciones medicamentosas)

  • CiclofosfamidainmunosupresorModerada

    Table 2: Drugs that Potentiate Cyclophosphamide Toxicities Toxicity Drugs Increased hematotoxicity and/or immunosuppression ● ACE inhibitors: ACE inhibitors can cause leukopenia. ● Natalizumab ● Paclitaxel: Increased hematotoxicity has been reported when cyclophosphamide was administered after paclitaxel infusion. ● Thiazide diuretics ● Zidovudine Increased cardiotoxicity… (etiqueta de Ciclofosfamida, Interacciones medicamentosas)

  • CiclosporinainmunosupresorModerada

    Caution is also required when cyclosporine is coadministered with potassium sparing drugs (e.g., angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists), potassium-containing drugs as well as in patients on a potassium rich diet. (etiqueta de Ciclosporina, Interacciones medicamentosas)

  • Clorotiazidadiurético tiazídicoModerada

    Experience with another ACE inhibitor suggests that these increases would be reversible upon discontinuation of ramipril and/or diuretic therapy. (etiqueta de Ramipril, Advertencias y precauciones)

  • Clortalidonadiurético tiazídicoModerada

    Experience with another ACE inhibitor suggests that these increases would be reversible upon discontinuation of ramipril and/or diuretic therapy. (etiqueta de Ramipril, Advertencias y precauciones)

  • Dexmetilfenidatoestimulante del SNCModerada

    • Antihypertensive Drugs: Monitor blood pressure. (etiqueta de Dexmetilfenidato, Interacciones medicamentosas)

  • DiclofenacoAINEModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect (7.6). mTOR inhibitor or neprilysin inhibitor use may increase angioedema risk (7.7). (etiqueta de Ramipril, Interacciones medicamentosas)

  • NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect (7.6). mTOR inhibitor or neprilysin inhibitor use may increase angioedema risk (7.7). (etiqueta de Ramipril, Interacciones medicamentosas)

  • DiflunisalAINEModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect (7.6). mTOR inhibitor or neprilysin inhibitor use may increase angioedema risk (7.7). (etiqueta de Ramipril, Interacciones medicamentosas)

  • DofetilidaantiarrítmicoModerada

    Concomitant medications were grouped as ACE inhibitors, oral anticoagulants, calcium channel blockers, beta blockers, cardiac glycosides, inducers of CYP3A4, substrates and inhibitors of CYP3A4, substrates and inhibitors of P-glycoprotein, nitrates, sulphonylureas, loop diuretics, potassium sparing diuretics, thiazide diuretics, substrates and inhibitors of tubular… (etiqueta de Dofetilida, Interacciones medicamentosas)

  • Drospirenona y etinilestradiolanticonceptivo oralModerada

    Medications that may increase serum potassium concentration include ACE inhibitors, angiotensin-II receptor antagonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDS. (etiqueta de Drospirenona y etinilestradiol, Advertencias y precauciones)

  • DuloxetinaIRSNModerada

    The risk of BP decreases may be greater in patients taking concomitant medications that induce orthostatic hypotension (such as antihypertensives) or are potent CYP1A2 inhibitors [see Drug Interactions ( 7.1 )] and in patients taking duloxetine delayed-release capsules at doses above 60 mg daily. (etiqueta de Duloxetina, Advertencias y precauciones)

  • Eplerenonaantagonista de la aldosteronaModerada

    Experience with another ACE inhibitor suggests that these increases would be reversible upon discontinuation of ramipril and/or diuretic therapy. (etiqueta de Ramipril, Advertencias y precauciones)

  • Following initiation and titration of Epogen, approximately 25% of patients on dialysis required initiation of or increases in antihypertensive therapy; hypertensive encephalopathy and seizures have been reported in patients with CKD receiving Epogen. (etiqueta de Epoetina alfa, Advertencias y precauciones)

  • Epoprostenolanálogo de prostaglandinaModerada

    Additional reductions in blood pressure may occur when VELETRI is administered with diuretics, antihypertensive agents, or other vasodilators. (etiqueta de Epoprostenol, Interacciones medicamentosas)

  • EsmololbetabloqueanteModerada

    Antihypertensive agents clonidine, guanfacine, or moxonidine: Beta blockers also increase the risk of clonidine-, guanfacine-, or moxonidine-withdrawal rebound hypertension. (etiqueta de Esmolol, Interacciones medicamentosas)

  • Espironolactonaantagonista de la aldosteronaModerada

    Experience with another ACE inhibitor suggests that these increases would be reversible upon discontinuation of ramipril and/or diuretic therapy. (etiqueta de Ramipril, Advertencias y precauciones)

  • Espironolactona e hidroclorotiazidaantagonista de la aldosteronaModerada

    Experience with another ACE inhibitor suggests that these increases would be reversible upon discontinuation of ramipril and/or diuretic therapy. (etiqueta de Ramipril, Advertencias y precauciones)

  • EtodolacoAINEModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect (7.6). mTOR inhibitor or neprilysin inhibitor use may increase angioedema risk (7.7). (etiqueta de Ramipril, Interacciones medicamentosas)

  • Fenelzinainhibidor de la MAOModerada

    …hydrochloride desipramine hydrochloride imipramine hydrochloride doxepin carbamazepine cyclobenzaprine HCl amoxapine maprotiline HCl trimipramine maleate protriptyline HCl mirtazapine Phenelzine sulfate should be used with caution in combination with antihypertensive drugs, including thiazide diuretics and β-blockers, since exaggerated hypotensive effects may result. (etiqueta de Fenelzina, Advertencias)

  • FenilefrinadescongestionanteModerada

    Antagonistic Effects (decrease in BIORPHEN blood pressure effect) can occur with α-adrenergic antagonists, phosphodiesterase Type 5 inhibitors, mixed α- and β-receptor antagonists, calcium channel blockers, benzodiazepines and ACE inhibitors, centrally acting sympatholytic agents. (etiqueta de Fenilefrina, Interacciones medicamentosas)

  • FenoprofenoAINEModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect (7.6). mTOR inhibitor or neprilysin inhibitor use may increase angioedema risk (7.7). (etiqueta de Ramipril, Interacciones medicamentosas)

  • FlurbiprofenoAINEModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect (7.6). mTOR inhibitor or neprilysin inhibitor use may increase angioedema risk (7.7). (etiqueta de Ramipril, Interacciones medicamentosas)

  • Furosemidadiurético de asaModerada

    Experience with another ACE inhibitor suggests that these increases would be reversible upon discontinuation of ramipril and/or diuretic therapy. (etiqueta de Ramipril, Advertencias y precauciones)

  • GlibenclamidasulfonilureaModerada

    Drug Interactions The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, ACE inhibitors, disopyramide, fluoxetine, clarithromycin, and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, monoamine oxidase inhibitors, and beta adrenergic blocking… (etiqueta de Glibenclamida, Interacciones medicamentosas)

  • GlimepiridasulfonilureaModerada

    …including glimepiride, increasing the susceptibility to and/or intensity of hypoglycemia: oral anti-diabetic medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H 2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine,… (etiqueta de Glimepirida, Interacciones medicamentosas)

  • GlipizidasulfonilureaModerada

    …following are examples of medication that may increase the glucose lowering effect of GLUCOTROL XL, increase the susceptibility to and/or intensity of hypoglycemia: antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin… (etiqueta de Glipizida, Interacciones medicamentosas)

  • Hidroclorotiazidadiurético tiazídicoModerada

    Experience with another ACE inhibitor suggests that these increases would be reversible upon discontinuation of ramipril and/or diuretic therapy. (etiqueta de Ramipril, Advertencias y precauciones)

  • NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect (7.6). mTOR inhibitor or neprilysin inhibitor use may increase angioedema risk (7.7). (etiqueta de Ramipril, Interacciones medicamentosas)

  • IbuprofenoAINEModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect (7.6). mTOR inhibitor or neprilysin inhibitor use may increase angioedema risk (7.7). (etiqueta de Ramipril, Interacciones medicamentosas)

  • NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect (7.6). mTOR inhibitor or neprilysin inhibitor use may increase angioedema risk (7.7). (etiqueta de Ramipril, Interacciones medicamentosas)

  • IloperidonaantipsicóticoModerada

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive medications), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and… (etiqueta de Iloperidona, Advertencias y precauciones)

  • Indapamidadiurético tiazídicoModerada

    Experience with another ACE inhibitor suggests that these increases would be reversible upon discontinuation of ramipril and/or diuretic therapy. (etiqueta de Ramipril, Advertencias y precauciones)

  • IndometacinaAINEModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect (7.6). mTOR inhibitor or neprilysin inhibitor use may increase angioedema risk (7.7). (etiqueta de Ramipril, Interacciones medicamentosas)

  • Insulina aspartainsulinaModerada

    Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analog (e.g., octreotide), and sulfonamide antibiotics. (etiqueta de Insulina asparta, Interacciones medicamentosas)

  • Insulina degludecinsulinaModerada

    Table 5: Clinically Significant Drug Interactions with Insulin Degludec Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide… (etiqueta de Insulina degludec, Interacciones medicamentosas)

  • Insulina detemirinsulinaModerada

    Table 6: Clinically Significant Drug Interactions with LEVEMIR Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide… (etiqueta de Insulina detemir, Interacciones medicamentosas)

  • Insulina glarginainsulinaModerada

    Table 8: Clinically Significant Drug Interactions with Insulin Glargine-yfgn Drugs that May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide… (etiqueta de Insulina glargina, Interacciones medicamentosas)

  • Insulina lisproinsulinaModerada

    Clinically Significant Drug Interactions with LYUMJEV Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. (etiqueta de Insulina lispro, Interacciones medicamentosas)

  • Clinically Significant Drug Interactions with AFREZZA Antidiabetic agents, Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blocking Agents, Disopyramide, Fibrates, Fluoxetine, Monoamine Oxidase Inhibitors, Pentoxifylline, Pramlintide, Salicylates, Somatostatin Analogs (e.g., octreotide), and Sulfonamide Antibiotics Prevention or Management Monitor… (etiqueta de Insulina regular (humana), Interacciones medicamentosas)

  • Irbesartánantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Dual Blockade of the Renin-Angiotensin System Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. (etiqueta de Ramipril, Advertencias y precauciones)

  • KetoprofenoAINEModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect (7.6). mTOR inhibitor or neprilysin inhibitor use may increase angioedema risk (7.7). (etiqueta de Ramipril, Interacciones medicamentosas)

  • KetorolacoAINEModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect (7.6). mTOR inhibitor or neprilysin inhibitor use may increase angioedema risk (7.7). (etiqueta de Ramipril, Interacciones medicamentosas)

  • Lantanoquelante de fosfatoModerada

    Examples of relevant classes of compounds where antacids have been demonstrated to reduce bioavailability include antibiotics (such as quinolones, ampicillin, and tetracyclines), thyroid hormones, ACE inhibitors, statin lipid regulators, and anti-malarials. (etiqueta de Lantano, Interacciones medicamentosas)

  • Litiofármaco serotoninérgicoModerada

    Lithium: Use with caution (7.4). (etiqueta de Ramipril, Interacciones medicamentosas)

  • Losartánantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Dual Blockade of the Renin-Angiotensin System Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. (etiqueta de Ramipril, Advertencias y precauciones)

  • Losartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Experience with another ACE inhibitor suggests that these increases would be reversible upon discontinuation of ramipril and/or diuretic therapy. (etiqueta de Ramipril, Advertencias y precauciones)

  • LumateperonaantipsicóticoModerada

    Orthostatic vital signs should be monitored in patients who are vulnerable to hypotension (e.g., elderly patients, patients with dehydration, hypovolemia, and concomitant treatment with antihypertensive drugs), patients with known cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure, or conduction abnormalities), and patients… (etiqueta de Lumateperona, Advertencias y precauciones)

  • LurasidonaantipsicóticoModerada

    Patients at increased risk of these adverse reactions or at increased risk of developing complications from hypotension include those with dehydration, hypovolemia, treatment with antihypertensive medication, history of cardiovascular disease (e.g., heart failure, myocardial infarction, ischemia, or conduction abnormalities), history of cerebrovascular disease,… (etiqueta de Lurasidona, Advertencias y precauciones)

  • MecamilaminaantihipertensivoModerada

    The action of Mecamylamine HCl may be potentiated by anesthesia, other antihypertensive drugs and alcohol. (etiqueta de Mecamilamina, Interacciones medicamentosas)

  • MeloxicamAINEModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect (7.6). mTOR inhibitor or neprilysin inhibitor use may increase angioedema risk (7.7). (etiqueta de Ramipril, Interacciones medicamentosas)

  • Metilfenidatoestimulante del SNCModerada

    Antihypertensive Drugs: Monitor blood pressure. (etiqueta de Metilfenidato, Interacciones medicamentosas)

  • Metoprolol e hidroclorotiazidabetabloqueanteModerada

    Experience with another ACE inhibitor suggests that these increases would be reversible upon discontinuation of ramipril and/or diuretic therapy. (etiqueta de Ramipril, Advertencias y precauciones)

  • MirtazapinaantidepresivoModerada

    REMERON/REMERONSolTab should be used with caution in patients with known cardiovascular or cerebrovascular disease that could be exacerbated by hypotension (history of myocardial infarction, angina, or ischemic stroke) and conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medication). (etiqueta de Mirtazapina, Advertencias y precauciones)

  • Modafiniloestimulante del SNCModerada

    However, a retrospective analysis of the use of antihypertensive medication in these studies showed that a greater proportion of patients on PROVIGIL required new or increased use of antihypertensive medications (2.4%) compared to patients on placebo (0.7%). (etiqueta de Modafinilo, Advertencias y precauciones)

  • NabumetonaAINEModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect (7.6). mTOR inhibitor or neprilysin inhibitor use may increase angioedema risk (7.7). (etiqueta de Ramipril, Interacciones medicamentosas)

  • NaproxenoAINEModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect (7.6). mTOR inhibitor or neprilysin inhibitor use may increase angioedema risk (7.7). (etiqueta de Ramipril, Interacciones medicamentosas)

  • NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect (7.6). mTOR inhibitor or neprilysin inhibitor use may increase angioedema risk (7.7). (etiqueta de Ramipril, Interacciones medicamentosas)

  • NiacinaModerada

    Antihypertensive Therapy Niacin may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension. (etiqueta de Niacina, Interacciones medicamentosas)

  • Nifedipinobloqueador de los canales de calcio dihidropiridínicoModerada

    ACE Inhibitors Benazepril: In healthy volunteers receiving single dose of 20 mg nifedipine ER and benazepril 10 mg, the plasma concentrations of benazeprilat and nifedipine in the presence and absence of each other were not statistically significantly different. (etiqueta de Nifedipino, Interacciones medicamentosas)

  • Nimodipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Blood Pressure Lowering Drugs Nimodipine may increase the blood pressure lowering effect of concomitantly administered anti-hypertensives such as diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, other calcium channel blockers, α-adrenergic blockers, PDE5 inhibitors, and α-methyldopa. (etiqueta de Nimodipino, Interacciones medicamentosas)

  • NitroglicerinanitratoModerada

    Antihypertensives: Possible additive hypotensive effects. (etiqueta de Nitroglicerina, Interacciones medicamentosas)

  • OlanzapinaantipsicóticoModerada

    …of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications) where the occurrence of syncope, or hypotension and/or bradycardia might put the patient at increased medical risk. (etiqueta de Olanzapina, Advertencias y precauciones)

  • Olanzapina y fluoxetinaantipsicóticoModerada

    …and fluoxetine capsules should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions that would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (etiqueta de Olanzapina y fluoxetina, Advertencias y precauciones)

  • Olmesartánantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Dual Blockade of the Renin-Angiotensin System Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. (etiqueta de Ramipril, Advertencias y precauciones)

  • Olmesartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Experience with another ACE inhibitor suggests that these increases would be reversible upon discontinuation of ramipril and/or diuretic therapy. (etiqueta de Ramipril, Advertencias y precauciones)

  • Olmesartán, amlodipino e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Experience with another ACE inhibitor suggests that these increases would be reversible upon discontinuation of ramipril and/or diuretic therapy. (etiqueta de Ramipril, Advertencias y precauciones)

  • NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect (7.6). mTOR inhibitor or neprilysin inhibitor use may increase angioedema risk (7.7). (etiqueta de Ramipril, Interacciones medicamentosas)

  • OxaprozinaAINEModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect (7.6). mTOR inhibitor or neprilysin inhibitor use may increase angioedema risk (7.7). (etiqueta de Ramipril, Interacciones medicamentosas)

  • PaliperidonaantipsicóticoModerada

    Use ERZOFRI with caution in patients with known cardiovascular disease (e.g., heart failure, history of myocardial infarction or ischemia, conduction abnormalities), cerebrovascular disease, or conditions that predispose the patient to hypotension (e.g., dehydration, hypovolemia, and treatment with antihypertensive medications). (etiqueta de Paliperidona, Advertencias y precauciones)

  • NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect (7.6). mTOR inhibitor or neprilysin inhibitor use may increase angioedema risk (7.7). (etiqueta de Ramipril, Interacciones medicamentosas)

  • PazopanibModerada

    Monitor blood pressure as clinically indicated and initiate and adjust antihypertensive therapy as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

  • PentoxifilinametilxantinaModerada

    Small decreases in blood pressure have been observed in some patients treated with pentoxifylline extended-release tablets; periodic systemic blood pressure monitoring is recommended for patients receiving concomitant antihypertensive therapy. (etiqueta de Pentoxifilina, Interacciones medicamentosas)

  • Pioglitazona y glimepiridatiazolidinedionaModerada

    …glimepiride tablets, increasing the susceptibility to and/or intensity of hypoglycemia: oral anti-diabetic medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine,… (etiqueta de Pioglitazona y glimepirida, Interacciones medicamentosas)

  • PiroxicamAINEModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect (7.6). mTOR inhibitor or neprilysin inhibitor use may increase angioedema risk (7.7). (etiqueta de Ramipril, Interacciones medicamentosas)

  • PrazosinaalfabloqueanteModerada

    Syncopal episodes have usually occurred within 30 to 90 minutes of the initial dose of the drug; occasionally, they have been reported in association with rapid dosage increases or the introduction of another antihypertensive drug into the regimen of a patient taking high doses of prazosin hydrochloride capsules. (etiqueta de Prazosina, Advertencias)

  • PregabalinaanticonvulsivoModerada

    In addition, patients who are taking other drugs associated with angioedema (e.g., angiotensin converting enzyme inhibitors [ACE-inhibitors]) may be at increased risk of developing angioedema. (etiqueta de Pregabalina, Advertencias y precauciones)

  • QuetiapinaantipsicóticoModerada

    Quetiapine should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure, or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (etiqueta de Quetiapina, Advertencias y precauciones)

  • RiociguatvasodilatadorModerada

    Consider the potential for symptomatic hypotension or ischemia in patients with hypovolemia, severe left ventricular outflow obstruction, resting hypotension, autonomic dysfunction, or concomitant treatment with antihypertensives or strong CYP and P-gp/BCRP inhibitors [see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ] . (etiqueta de Riociguat, Advertencias y precauciones)

  • RisperidonaantipsicóticoModerada

    Clinically significant hypotension has been observed with concomitant use of oral RISPERDAL and antihypertensive medication. (etiqueta de Risperidona, Advertencias y precauciones)

  • SalsalatoAINEModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect (7.6). mTOR inhibitor or neprilysin inhibitor use may increase angioedema risk (7.7). (etiqueta de Ramipril, Interacciones medicamentosas)

  • Sildenafiloinhibidor de la PDE5Moderada

    Caution is advised when SILDENAFIL ORAL FILM is co-administered with alpha-blockers or antihypertensives. (etiqueta de Sildenafilo, Advertencias y precauciones)

  • SilodosinaalfabloqueanteModerada

    However, patients in the Phase 3 clinical studies taking concomitant antihypertensive medications with silodosin capsules did not experience a significant increase in the incidence of syncope, dizziness, or orthostasis. (etiqueta de Silodosina, Advertencias y precauciones)

  • SirolimusinmunosupresorModerada

    The concomitant use of sirolimus with other drugs known to cause angioedema, such as angiotensin converting enzyme (ACE) inhibitors, may increase the risk of developing angioedema. (etiqueta de Sirolimus, Advertencias y precauciones)

  • SorafenibModerada

    Consider temporary or permanent discontinuation for severe or persistent hypertension despite antihypertensive therapy. (etiqueta de Sorafenib, Advertencias y precauciones)

  • In the literature, three cases of hyperkalemia in elderly patients have been reported after concomitant intake of sulfamethoxazole/trimethoprim and an angiotensin converting enzyme inhibitor. (etiqueta de Sulfametoxazol y trimetoprima, Interacciones medicamentosas)

  • SulindacoAINEModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect (7.6). mTOR inhibitor or neprilysin inhibitor use may increase angioedema risk (7.7). (etiqueta de Ramipril, Interacciones medicamentosas)

  • Sumatriptán y naproxenotriptánModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect (7.6). mTOR inhibitor or neprilysin inhibitor use may increase angioedema risk (7.7). (etiqueta de Ramipril, Interacciones medicamentosas)

  • SunitinibModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • TacrolimusinmunosupresorModerada

    • Hypertension: May require antihypertensive therapy; monitor relevant drug interactions. (etiqueta de Tacrolimus, Advertencias y precauciones)

  • TemsirolimusModerada

    Patients taking concomitant mammalian target of rapamycin (mTOR) inhibitor (e.g. temsirolimus) therapy or a neprilysin inhibitor may be at increased risk for angioedema [see Drug Interactions (7.7) ]. (etiqueta de Ramipril, Advertencias y precauciones)

  • TerazosinaalfabloqueanteModerada

    Risk of Hypotension with Concomitant Use of Other Antihypertensive Agents and Phospodiesterase Type 5 Inhibitors (PDE5-I): Concomitant administration of TEZRULY with antihypertensives or phosphodiesterase-5 (PDE-5) inhibitors can result in additive blood pressure lowering effects and symptomatic hypotension (5.3). (etiqueta de Terazosina, Advertencias y precauciones)

  • TestosteronaandrógenoModerada

    In patients with hypertension on antihypertensive therapy, TLANDO increased the mean systolic/diastolic BP by 4.8/1.6 mm Hg from baseline. [see Adverse Reactions ( 6.1 )] . (etiqueta de Testosterona, Advertencias y precauciones)

  • TolmetinaAINEModerada

    NSAIDS use may lead to increased risk of renal impairment and loss of antihypertensive effect (7.6). mTOR inhibitor or neprilysin inhibitor use may increase angioedema risk (7.7). (etiqueta de Ramipril, Interacciones medicamentosas)

  • TolvaptánModerada

    Monitor serum potassium during concomitant therapy with ( 7.2 ): Angiotensin receptor blockers Angiotensin converting enzyme inhibitors Potassium sparing diuretics 7.1 CYP3A Inhibitors and Inducers Strong CYP3A Inhibitors Tolvaptan's AUC was 5.4 times as large and C max was 3.5 times as large after co-administration of tolvaptan and 200 mg ketoconazole [see Warnings… (etiqueta de Tolvaptán, Interacciones medicamentosas)

  • Torasemidadiurético de asaModerada

    Experience with another ACE inhibitor suggests that these increases would be reversible upon discontinuation of ramipril and/or diuretic therapy. (etiqueta de Ramipril, Advertencias y precauciones)

  • TrazodonaantidepresivoModerada

    Concomitant use with an antihypertensive may require a reduction in the dose of the antihypertensive drug. (etiqueta de Trazodona, Advertencias y precauciones)

  • Triamterenodiurético ahorrador de potasioModerada

    Experience with another ACE inhibitor suggests that these increases would be reversible upon discontinuation of ramipril and/or diuretic therapy. (etiqueta de Ramipril, Advertencias y precauciones)

  • Triamtereno e hidroclorotiazidadiurético ahorrador de potasioModerada

    Experience with another ACE inhibitor suggests that these increases would be reversible upon discontinuation of ramipril and/or diuretic therapy. (etiqueta de Ramipril, Advertencias y precauciones)

  • Vardenafiloinhibidor de la PDE5Moderada

    Vardenafil hydrochloride tablets can potentiate the hypotensive effects of nitrates, alpha- blockers, and antihypertensives. (etiqueta de Vardenafilo, Interacciones medicamentosas)

  • VenlafaxinaIRSNModerada

    Metoprolol: Possibly reduced blood-pressure lowering effect despite increased metoprolol plasma levels. (etiqueta de Venlafaxina, Interacciones medicamentosas)

  • Verapamilobloqueador de los canales de calcioModerada

    Antihypertensive Agents Verapamil administered concomitantly with oral antihypertensive agents (e.g., vasodilators, angiotensin-converting enzyme inhibitors, diuretics, beta blockers) will usually have an additive effect on lowering blood pressure. (etiqueta de Verapamilo, Interacciones medicamentosas)

  • Concurrent use with potassium-containing medications, potassium-sparing diuretics and angiotensin-converting enzyme inhibitors (ACE inhibitors) may result in hyperkalemia and cardiac arrhythmias or cardiac arrest. (etiqueta de Yoduro de potasio, Interacciones medicamentosas)

  • ZiprasidonaantipsicóticoModerada

    Ziprasidone should be used with particular caution in patients with known cardiovascular disease (history of myocardial infarction or ischemic heart disease, heart failure or conduction abnormalities), cerebrovascular disease, or conditions which would predispose patients to hypotension (dehydration, hypovolemia, and treatment with antihypertensive medications). (etiqueta de Ziprasidona, Advertencias y precauciones)

Menciones leves (28)

  • Articaína y adrenalinaanestésico localLeve

    Where there is involvement of the tongue, glottis, or larynx likely to cause airway obstruction, administer appropriate therapy (e.g., subcutaneous epinephrine solution 1:1000 [0.3 mL to 0.5 mL]) promptly [see Adverse Reactions ( 6 )]. (etiqueta de Ramipril, Advertencias y precauciones)

  • AzatioprinainmunosupresorLeve

    Use with Angiotensin-Converting Enzyme Inhibitors: The use of angiotensin-converting enzyme inhibitors to control hypertension in patients on azathioprine has been reported to induce anemia and severe leukopenia. (etiqueta de Azatioprina, Interacciones medicamentosas)

  • Bupivacaína y adrenalinaanestésico localLeve

    Where there is involvement of the tongue, glottis, or larynx likely to cause airway obstruction, administer appropriate therapy (e.g., subcutaneous epinephrine solution 1:1000 [0.3 mL to 0.5 mL]) promptly [see Adverse Reactions ( 6 )]. (etiqueta de Ramipril, Advertencias y precauciones)

  • ButorfanolopioideLeve

    In such cases, butorphanol should be discontinued and the hypertension treated with antihypertensive drugs. (etiqueta de Butorfanol, Advertencias)

  • CidofovirantiviralLeve

    Drug Interactions Probenecid Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline,… (etiqueta de Cidofovir, Interacciones medicamentosas)

  • Citrato de potasiosuplemento de potasioLeve

    Renin-Angiotensin-Aldosterone System Inhibitors 7.3 Renin-Angiotensin-Aldosterone System Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (etiqueta de Citrato de potasio, Interacciones medicamentosas)

  • ClorpromazinaantipsicóticoLeve

    Chlorpromazine may counteract the antihypertensive effect of guanethidine and related compounds. (etiqueta de Clorpromazina, Advertencias)

  • Cloruro de potasiosuplemento de potasioLeve

    Renin-angiotensin-aldosterone Inhibitors Drugs that inhibit the renin-angiotensin-aldosterone system (RAAS) including angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), spironolactone, eplerenone, or aliskiren produce potassium retention by inhibiting aldosterone production. (etiqueta de Cloruro de potasio, Interacciones medicamentosas)

  • Desipraminaantidepresivo tricíclicoLeve

    This drug is capable of blocking the antihypertensive effect of guanethidine and similarly acting compounds. (etiqueta de Desipramina, Advertencias)

  • Desogestrel y etinilestradiolanticonceptivo oralLeve

    If other contraceptive methods are not suitable, hormonal contraceptive therapy may continue combined with antihypertensive therapy. (etiqueta de Desogestrel y etinilestradiol, Advertencias)

  • Dexanfetaminaestimulante del SNCLeve

    Antihypertensives Amphetamines may antagonize the hypotensive effects of antihypertensives. (etiqueta de Dexanfetamina, Interacciones medicamentosas)

  • EfedrinasimpaticomiméticoLeve

    Examples: α-adrenergic antagonists, β-adrenergic receptor antagonists, reserpine, quinidine, mephentermine Other Drug Interactions G u anethidine C linical Impact: Ephedrine may inhibit the neuron blockage produced by guanethidine, resulting in loss of antihypertensive effectiveness. (etiqueta de Efedrina, Interacciones medicamentosas)

  • Finasteridainhibidor de la 5-alfa reductasaLeve

    …specific interaction studies were not performed, PROSCAR was concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, α-blockers, angiotensin-converting enzyme (ACE) inhibitors, analgesics, anti-convulsants, beta-adrenergic blocking agents, diuretics, calcium channel blockers, cardiac nitrates, HMG-CoA reductase inhibitors, nonsteroidal anti-inflammatory… (etiqueta de Finasterida, Interacciones medicamentosas)

  • HidralazinavasodilatadorLeve

    When other potent parenteral antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure. (etiqueta de Hidralazina, Interacciones medicamentosas)

  • ACE Inhibitors FIRAZYR is a bradykinin B2 receptor antagonist and thereby has the potential to have a pharmacodynamic interaction with ACE inhibitors where FIRAZYR may attenuate the antihypertensive effect of ACE inhibitors. (etiqueta de Icatibant, Interacciones medicamentosas)

  • Isradipinobloqueador de los canales de calcio dihidropiridínicoLeve

    In a study in hypertensive patients, addition of isradipine to existing hydrochlorothiazide therapy did not result in any unexpected adverse effects, and isradipine had an additional antihypertensive effect. (etiqueta de Isradipino, Interacciones medicamentosas)

  • Lidocaína y adrenalinaanestésico localLeve

    Where there is involvement of the tongue, glottis, or larynx likely to cause airway obstruction, administer appropriate therapy (e.g., subcutaneous epinephrine solution 1:1000 [0.3 mL to 0.5 mL]) promptly [see Adverse Reactions ( 6 )]. (etiqueta de Ramipril, Advertencias y precauciones)

  • MetildopaantihipertensivoLeve

    Drug Interactions When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. (etiqueta de Metildopa, Interacciones medicamentosas)

  • MetoprololbetabloqueanteLeve

    Because of its relative beta 1 cardio-selectivity, however, Metoprolol Tartrate Tablets may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. (etiqueta de Metoprolol, Advertencias y precauciones)

  • MexiletinaantiarrítmicoLeve

    In a large compassionate use program mexiletine has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions. (etiqueta de Mexiletina, Interacciones medicamentosas)

  • Nisoldipinobloqueador de los canales de calcio dihidropiridínicoLeve

    The blood pressure effect of SULAR tended to be greater in patients on atenolol than in patients on no other antihypertensive therapy. (etiqueta de Nisoldipino, Interacciones medicamentosas)

  • NitroprusiatovasodilatadorLeve

    Hypertensive patients, and patients concomitantly receiving other antihypertensive medications, may be more sensitive to the effects of sodium nitroprusside than normal subjects. (etiqueta de Nitroprusiato, Advertencias)

  • Nortriptilinaantidepresivo tricíclicoLeve

    The antihypertensive action of guanethidine and similar agents may be blocked. (etiqueta de Nortriptilina, Advertencias)

  • Prilocaína y adrenalinaanestésico localLeve

    Where there is involvement of the tongue, glottis, or larynx likely to cause airway obstruction, administer appropriate therapy (e.g., subcutaneous epinephrine solution 1:1000 [0.3 mL to 0.5 mL]) promptly [see Adverse Reactions ( 6 )]. (etiqueta de Ramipril, Advertencias y precauciones)

  • ProclorperazinaantipsicóticoLeve

    Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concomitantly. (etiqueta de Proclorperazina, Precauciones)

  • Protriptilinaantidepresivo tricíclicoLeve

    Protriptyline may block the antihypertensive effect of guanethidine or similarly acting compounds. (etiqueta de Protriptilina, Advertencias)

  • RepaglinidameglitinidaLeve

    Examples: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, nonsteroidal anti-inflammatory agents (NSAIDs), pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. (etiqueta de Repaglinida, Interacciones medicamentosas)

  • TrifluoperazinaantipsicóticoLeve

    Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concurrently. (etiqueta de Trifluoperazina, Precauciones)

Compruebe Ramipril frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.

Abrir en el verificador

No es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.